MAIA Biotechnology announces $1.51M private placement of common stock and warrants

MAIA Biotechnology, Inc.

Gross proceeds ~$1.51M from 1,233,488 shares at $1.224 each, with warrants exercisable at $1.36.
Warrants exercisable six months after issuance, three-year term, priced at NYSE American minimum price.
Directors subscribe for 179,737 shares (~$220k); Louie Ngar Yee, Stan Smith, Steven Chaouki.
Net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.
Expected close Dec 18, 2025; securities unregistered, offered under Section 4(a)(2)/Reg D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.